This week, there are various hot topics in the financing of the medical and health field. Ganewei Medical’s multi hundred million yuan C-round enhanced tumor ablation robot; Kejun Pharmaceutical’s Series C promotion of innovative cardiovascular and cerebrovascular drugs with over 300 million yuan; Brain recording million level financing layout, motion brain computer interface; Lingjiang Medical and Hechen Biotechnology are respectively focusing on the industrialization of high-end biomaterials and synthetic biology; Tianhong Shengjie consolidates its leading position in intravenous intervention; Zean is investing 38 million US dollars to promote immune therapy using myeloid cell connectors. The seven major projects highlight the strong development vitality and broad market prospects of the medical and health hard technology track.

1、 Ganewei Medical has completed hundreds of millions of yuan in Series C financing, leading the era of precision tumor ablation and “intelligent control”

Under the trend of precision and intelligent iteration in the global minimally invasive tumor intervention track, the leading domestic intervention enterprise Ganewei Medical recently announced the completion of hundreds of millions of yuan in Series C financing. This round of financing is invested by multiple well-known medical industry funds, with old shareholders joining in, fully reflecting the recognition of capital for domestically produced original intervention hard technology.
Ganewei Medical has established a full process product matrix of “percutaneous intervention navigation robot+precise energy ablation+intelligent biopsy and consumables”, covering the entire process of tumor intervention diagnosis and treatment, and laying out multiple cutting-edge original technologies for the pain points of percutaneous treatment of complex organs such as liver and lung. Its core percutaneous intervention surgical robot combines clear clinical value and industry chain synergy advantages, which can significantly improve puncture accuracy, reduce operator learning curve, and minimize surgical complications, with outstanding differentiated competitive advantages.

In recent years, the national and multiple provincial and municipal medical insurance bureaus have successively issued a catalog of surgical robot fees, which has opened up a payment channel for the commercialization of domestic surgical robots and opened up industry growth space. The funds raised in this round of financing will be used for the clinical translation and commercial promotion of intelligent intervention new technologies, accelerating the ecological construction of the Ganewei minimally invasive intervention overall platform. By 2025, Ganewei Medical has won multiple industry honors with its technological innovation strength. In the future, the company will adhere to its established technology strategy, expand research and development boundaries and indications coverage, accelerate international layout, and promote precise tumor ablation to officially enter a new era of intelligent control.

2、 Kejun Pharmaceutical has completed over 300 million Series C financing to accelerate the development of innovative drugs

In the first quarter of 2026, domestic original innovative drug enterprise Kejun Pharmaceutical announced the completion of over 300 million yuan in Series C financing. This round is led by domestic biopharmaceutical leader Watson Biosciences and co invested by professional institutions such as Taikun Fund under Tailong Capital.

Founded in Shanghai in 2018, Kejun Pharmaceutical has built two differentiated independent technology platforms around unmet clinical needs in the fields of cardiovascular, metabolic, and antiviral medicine: the “Aosheng” mRNA technology platform and the “Puyu” prodrug technology platform, forming a virtuous development logic of technology empowerment pipeline and pipeline feedback technology. The company’s core product, Foley, is the world’s first in class P2Y12 receptor inhibitor. With differentiated molecular design, it solves the bleeding risk pain points of existing similar drugs. Currently, multi center clinical trials have been conducted simultaneously in China and the United States, and the development progress ranks first in the world. In addition, the company’s candidate drug CG-0416 has entered phase I clinical trials, and CG-1999 has demonstrated clear therapeutic synergistic effects in preclinical animal models, with a clear overall pipeline gradient and outstanding value.

The funds from this round of financing will be used in three main directions: accelerating the global clinical development of core pipelines, upgrading the processes of two major technology platforms, and preparing IND applications for multiple preclinical candidate compounds. The joint investment of industrial capital and professional investment institutions fully reflects the market’s recognition of Kejun Pharmaceutical’s original innovation capabilities, which will help the company accelerate the transformation of achievements and promote high-quality innovative drugs to benefit patients worldwide.

3、 Sports Brain Computer Interface Enterprise Brain Retrieval Achieves Millions of Financing, Accelerating Product Commercialization

Recently, Beijing Naohuilu Technology Co., Ltd., which focuses on the development of non-invasive brain computer interfaces for sports and health scenarios, announced the completion of a multi million seed+round of financing. This round is led by Nanshan Zhanxin Investment, and the company’s previous seed round was invested by Qiji Chuangtan Investment. This round of funding will be used for core technology iteration, product engineering development, and market expansion, promoting the commercialization of non-invasive brain computer interface wearable devices in sports scenarios.

The current global brain computer interface industry has entered a period of commercial explosion, and 2025 is recognized by the industry as the first year of China’s brain computer interface industry. The track layout is gradually extending from clinical medical fields such as neurological rehabilitation to public health consumption scenarios. At present, the mainstream mass exercise monitoring system only covers peripheral physiological indicators such as heart rate and blood oxygen. There is a clear market gap in brain neural activity monitoring and exercise ability evaluation tools. Brain echo recording targets this segmented pain point and innovatively integrates AI algorithms and non-invasive EEG signal processing technology to build a complete service loop of “EEG monitoring nerve function evaluation personalized exercise guidance”, solving the industry pain points of low signal-to-noise ratio of EEG signals and insufficient portability of wearable devices in mass scenarios.

The core team of the company comes from universities such as Tsinghua University and Shanghai Jiao Tong University, covering the interdisciplinary fields of neuroscience, electronic engineering, and sports science; At present, the Neuromova N1 intelligent headband prototype has been launched and won the Golden Dot Design Award. After this round of financing, the product iteration and mass production will be accelerated, and the global commercial layout will be launched simultaneously. The landing progress of its mass motion brain computer interface deserves continuous attention from the industry.

4、 Lingjie Medical has completed tens of millions of yuan in A+round financing, focusing on the field of high-performance materials

Recently, Shanghai Lingjiang Medical Technology Co., Ltd., a high-end medical biomaterials enterprise in China, announced the completion of tens of millions of yuan in A+round financing. This round is jointly invested by Futeng Capital and Shanghai Fengxian Fund, with Kaicheng Capital serving as the exclusive financial advisor. The financing funds will be used for the preparation of large-scale production before the launch of core products, the establishment of a national commercial system, and the construction of sales networks. In conjunction with the rapid landing of core three types of medical devices after approval, Lingzhi Medical has launched a new round of financing, which is planned for the construction of a new production base.

Lingjian Medical was established in 2017 and is a typical technology driven transformation project. The core R&D team is led by Professor Zhu Linyong and holds dozens of original biological material invention patents. The technological achievements combine academic innovation and industrial transformation value. Currently, the business covers medical fields such as surgery and dermatology, and will expand to incremental tracks such as medical aesthetics and tissue engineering in the future.

The breakthrough of the company’s core industry lies in overcoming the technical pain point of large-scale industrialized preparation of high-intensity photosensitive hydrogel and breaking the overseas patent monopoly. At present, many low value medical products have been commercialized. The core product, light curing wound sealing glue, is expected to obtain three types of medical device registration certificates within this year. This product can meet the clinical needs of rapid sealing and leakage prevention of surgical wounds, and can replace traditional sutures and staples, with broad market space. The investors in this round stated that high-end medical biomaterials are currently the core track for domestic substitution. Based on original technology, Lingzhi Medical has connected the entire chain from laboratory to industrialization, with outstanding growth potential. All parties are unanimously optimistic about the company’s long-term development prospects.

5、 HeChen Biotechnology has completed a Series A financing of over 100 million yuan, accelerating the research and industrialization process of biomanufacturing

Recently, Hefei Hechen Biotechnology Co., Ltd. announced the completion of a Series A financing of over 100 million yuan, with investors including Anhui Provincial Venture Capital and other industries and state-owned capital institutions, and Xiqiao Capital serving as the exclusive financial advisor. The funds raised in this round of financing will be mainly used for the construction of a thousand ton production base and the introduction of an AI synthetic biology research and development platform, accelerating the development and industrialization of core pipelines.

Founded in 2022, HeChen Biotechnology has taken a differentiated “synthetic biology+precision chemistry” cross technology route, built a full chain capability from molecular design to large-scale scaling, and laid out two high value-added business segments: special materials and nutrition and health. Its pipeline covers multiple segmented fields with domestic substitution gaps, such as special high molecular weight material monomers, pharmaceutical grade small variety amino acids, and drug delivery formulation solutions. The company plans to complete the mass production pilot test of its core products by 2025, and the construction of a thousand ton production base has entered the sprint stage.

The thousand ton level base constructed in this round of investment will break through the common transformation breakpoint of “research and development pilot scale mass production” in the field of synthetic biology, achieving capacity improvement and production cost optimization; Introducing AI development tools can shorten the strain modification and process development cycle by over 30%, significantly improving research and development efficiency. The successful completion of this Series A financing will inject strong impetus into the production capacity construction and technological upgrading of HeChen Biotechnology, help the enterprise accelerate the landing of core products, further fill the gap in domestic substitution in related fields, and consolidate its differentiated competitive advantage in the cross disciplinary field of synthetic biology.

6、 Tianhong Shengjie, a leading Chinese intravenous intervention device company, has completed tens of millions of yuan in equity financing

Recently, Tianhong Shengjie, a leading domestic intravenous intervention device company, announced the completion of tens of millions of yuan in equity financing. This round of financing is exclusively invested by Chuangjing Capital, with Kaicheng Capital serving as the exclusive financial advisor. Peripheral vascular intervention is currently a thriving golden track in the medical device field, divided into two major sub sectors: arterial and venous. The overall penetration rate of interventional surgery in China is much lower than that in mature markets in Europe and America. Among them, the venous field has a low localization rate due to late clinical recognition and high product development barriers; With the increase of incidence rate of lower limb deep vein thrombosis, iliac vein compression syndrome and other diseases, and the popularization of clinical diagnosis and treatment standards, the track has broad growth potential, and there is huge room for domestic substitution.

Tianhong Shengjie was founded in 2016, adhering to the concept of “solving clinical pain points and adhering to domestic originality”, and taking the lead in achieving full coverage of interventional devices for peripheral venous diseases, providing one-stop diagnosis and treatment solutions. The company’s core product Venastent ® The iliac vein stent system, with its design advantage of adapting to the anatomical structure of Chinese blood vessels and excellent long-term clinical prognosis, has a stable market share in the first tier in China, breaking the long-term monopoly of overseas brands.

At the commercialization level, Tianhong Shengjie has established a specialized sales network covering the core medical market nationwide, fully benefiting from the policy of volume based procurement and achieving rapid growth in performance; At the same time, relying on the technology and channel accumulation in the field of veins, we have successfully promoted the layout of peripheral arterial pipelines and achieved coordinated growth in the “vein+artery” dual track. The funds from this round of financing will continue to be invested in research and development and market expansion, helping the company consolidate its leading position in intravenous intervention.

7、 Ze’an completes $38 million financing to advance the “myeloid cell adapter” immunotherapy pipeline

Tumor immunity has entered a breakthrough stage of subdivision, and myeloid targeted innovative therapies have received capital injection again. On May 6th, Zean Biopharmaceutical, which focuses on the development of a differentiated “myeloid cell adapter” platform, announced the completion of a new round of financing of $38 million. This round is led by Hillhouse and supplemented by multiple existing shareholders. The company’s cumulative financing scale since its establishment in 2022 has reached approximately $130 million.

The current mainstream global tumor immunotherapy mostly focuses on the T cell pathway, and the immune suppression mediated by myeloid cells in solid tumors is the core bottleneck of existing therapies with low resistance and response rates. Myeloid immune linkage has become one of the most promising frontier tracks in the global innovative drug field. Based on the research and development logic of “reverse transformation science” and combined with deep biological analysis of the tumor microenvironment, Zean has created a differentiated pipeline: the core variety LTZ-301 has entered phase I clinical trials, and preclinical studies have verified its outstanding anti-tumor activity and safety advantages. This round of financing will accelerate its phase I clinical climbing and queue expansion; The second candidate drug LTZ-232 will accelerate the IND application and phase I clinical launch, further improving the company’s pipeline gradient layout.

Dr. Li Jinze, founder of Zean, stated that this round of financing will support the company in achieving a strategic leap in research and development. The project leader of Hillhouse Venture Capital also clearly recognizes the team’s research and development capabilities and the long-term commercial value of the platform. With the completion of financing, the company has appointed Erin Lavelle, a global clinical development expert, as an independent director to provide strategic support for the global promotion of the pipeline.

About Us

MeritsIP: Your Global Intellectual Property Partner

At MeritsIP, we provide comprehensive IP services in biomedicine, medical devices, manufacturing, semiconductors, and AI. We support 200+ top clients globally with strategic, high-quality IP services.

Stay Connected

• • Website: https://www.meritsipglobal.com

• • LinkedIn: Follow us on LinkedIn

• • Email: meritsip@meritsandtree.com

© 2025 MeritsIP. All Rights Reserved.